Acceleron Pharma Inc. — Operating Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/75689ede-d76d-4c78-be0a-0ed64bf7bb86/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2020 | $-167.3M | 2020-01-01 – 2020-12-31 | evidence 0001280600-21-000017 |
| FY 2019 | $-136.4M | 2019-01-01 – 2019-12-31 | evidence 0001280600-20-000012 |
| FY 2018 | $-124.4M | 2018-01-01 – 2018-12-31 | evidence 0001280600-19-000012 |
| FY 2017 | $-110.0M | 2017-01-01 – 2017-12-31 | evidence 0001280600-18-000016 |
| FY 2016 | $-66.1M | 2016-01-01 – 2016-12-31 | evidence 0001280600-17-000008 |
| FY 2015 | $-60.9M | 2015-01-01 – 2015-12-31 | evidence 0001280600-16-000072 |
| FY 2014 | $-55.5M | 2014-01-01 – 2014-12-31 | evidence 0001280600-15-000009 |
| FY 2013 | $7.0M | 2013-01-01 – 2013-12-31 | evidence 0001047469-14-002530 |
| FY 2012 | $-28.9M | 2012-01-01 – 2012-12-31 | evidence 0001047469-14-002530 |
| FY 2011 | $38.6M | 2011-01-01 – 2011-12-31 | evidence 0001047469-14-002530 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).